SpineGuard Reports Third-quarter 2022 Revenue
04 Octobre 2022 - 6:00PM
Business Wire
- Q3 revenue growth of +44% at € 1.5 M (vs. 2021 Q3)
Regulatory News:
SpineGuard (FR0011464452 – ALSGD), an innovative company that
deploys its DSG® (Dynamic Surgical Guidance) sensing technology to
secure and streamline the placement of bone implants, announced
today that its revenue was € 1.5 M in the third quarter up 44% and
€ 4.0 M YTD up 24%.
Pierre JEROME, Chairman, CEO and Co-founder of SpineGuard,
said: “SpineGuard’s sales growth continues to accelerate in Q3
thanks to our strategic partnerships, with Omnia Medical in adult
spinal surgery, with WishBone Medical in pediatric orthopedics and
with ConfiDent in dental implantology. This momentum is also driven
by the recent FDA clearance for the use of our PediGuard device in
anterior surgery, by a large tender won in Saudi Arabia and by the
global pre-launch of our DSG Connect interface. Close to 400
procedures have already been performed by forty surgeons across the
globe with this new digital platform. We will be officially
launching it next week in Chicago at the occasion of the NASS
(North American Spine Society) congress and the week after at the
Eurospine in Milan. Our innovation pipeline is extremely promising
too. It will enable us to fuel this strong commercial activity and
initiate other partnerships.”
€ thousands – IFRS
Unaudited
2022
2021
Variance as reported
Variance c.c
First Quarter
1,131
1,049
+8%
+3%
Second Quarter
1,415
1,179
+20%
+10%
Half-Year
2,546
2,228
+14%
+6%
Third Quarter
1,476
1,022
+44%
+29%
Year to Date 9 Months
4,022
3,250
+24%
+13%
SpineGuard’s consolidated revenue increased 44% as reported and
29% in constant currency (cc) in Q3 compared to last year. Outside
the USA, the revenue increased by 42% compared to the third quarter
of 2021 while in the USA, the increase was 46% (+24 cc).
Over the first 9 months of the financial year, revenue increased
26% outside the Unites States and +23% in the USA (9% cc) and 24%
globally (13% cc) to € 4,022 K compared to € 3,250 K for the same
period in 2021. 4,209 DSG equipped units were sold in the first
nine months of 2022 (1,983 in the USA, 47% of total units sold)
compared with 3,898 in the first nine months of 2021.
SpineGuard’s Priorities
SpineGuard is focusing on the following priorities while
investing selectively to remain close to breakeven:
- Boost commercial activities with the launch of the DSG-Connect
visual interface and the partnership with WishBone Medical
- Deploy the DSG digital technology in the surgical robotic
field
- Develop a Smart Universal Drill (SUD) embedding the DSG
artificial intelligence
- Support ConfiDent with the design and scale-up of the DSG
dental applications
- Implement the agreement recently signed with Omnia Medical
- Sign other strategic partnerships
Webinar in French on November 10, 2022, at 10:30 am
CET
SpineGuard’s management invites its shareholders to attend a
webinar to discuss Company news, update on its business
partnerships, the ramp-up of its commercial activity and its
product innovations as well as than its prospects. Register
here
About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and
Stéphane Bette, SpineGuard is an innovative company deploying its
proprietary radiation-free real time sensing technology DSG®
(Dynamic Surgical Guidance) to secure and streamline the placement
of implants in the skeleton. SpineGuard designs, develops and
markets medical devices that have been used in over 90,000 surgical
procedures worldwide. Nineteen studies published in peer-reviewed
scientific journals have demonstrated the multiple benefits DSG®
offers to patients, surgeons, surgical staff and hospitals.
Building on these strong fundamentals and several strategic
partnerships, SpineGuard has expanded the scope of its DSG®
technology in innovative applications such as the « smart » pedicle
screw, the DSG Connect visualization and registration interface,
dental implantology and surgical robotics. DSG® was co-invented by
Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain
Vanquaethem, Biomedical Engineer. SpineGuard has engaged in
multiple ESG initiatives.
For further information, visit www.spineguard.com
Disclaimer
The SpineGuard securities may not be offered or sold in the
United States as they have not been and will not be registered
under the Securities Act or any United States state securities
laws, and SpineGuard does not intend to make a public offer of its
securities in the United States. This is an announcement and not a
prospectus, and the information contained herein does and shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of the securities referred to herein in
the United States in which such offer, solicitation or sale would
be unlawful prior to registration or exemption from
registration.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221004005875/en/
SpineGuard Pierre Jérôme CEO & Chairman Tel: +33 1 45
18 45 19 p.jerome@spineguard.com
SpineGuard Manuel Lanfossi CFO Tel: +33 1 45 18 45 19
m.lanfossi@spineguard.com
NewCap Investor Relations & Financial Communication
Mathilde Bohin / Aurélie Manavarere Tel: +33 1 44 71 94 94
spineguard@newcap.eu
Spineguard (EU:ALSGD)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Spineguard (EU:ALSGD)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024